
## Tim Meyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7555518/publications.pdf Version: 2024-02-01



TIM MEVED

#	Article	IF	CITATIONS
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet, The, 2017, 389, 2492-2502.	13.7	3,224
2	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. New England Journal of Medicine, 2018, 379, 54-63.	27.0	1,677
3	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	13.7	1,475
4	Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies. CardioVascular and Interventional Radiology, 2007, 30, 6-25.	2.0	698
5	Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 293-313.	17.8	428
6	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 565-575.	8.1	362
7	EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. Journal of Hepatology, 2011, 55, 1309-1316.	3.7	286
8	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	21.4	275
9	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology, 2021, 73, 158-191.	7.3	235
10	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 320-341.	3.7	165
11	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 1038.	4.3	154
12	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Clinical Cancer Research, 2016, 22, 250-258.	7.0	149
13	Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. Journal of Clinical Oncology, 2013, 31, 365-372.	1.6	148
14	Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 1652-1664.	10.7	108
15	Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors. Clinical Cancer Research, 2011, 17, 337-345.	7.0	99
16	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Responseâ€Based Approach. Hepatology, 2020, 72, 198-212.	7.3	92
17	MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clinical Cancer Research, 2020, 26, 3936-3946.	7.0	86
18	A multicentre comparison between Child Pugh and Albuminâ€Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International, 2016, 36, 1821-1828.	3.9	85

Tim Meyer

#	Article	IF	CITATIONS
19	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study Journal of Clinical Oncology, 2017, 35, 4013-4013.	1.6	76
20	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 3069.	3.3	74
21	A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. Clinical Cancer Research, 2009, 15, 4484-4492.	7.0	68
22	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. British Journal of Cancer, 2017, 116, 448-454.	6.4	66
23	Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clinical Cancer Research, 2016, 22, 79-85.	7.0	65
24	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-NaÃ <sup>-</sup> ve Advanced Pancreatic Neuroendocrine Tumors. Oncologist, 2018, 23, 766-e90.	3.7	59
25	<scp>mRECIST</scp> to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase <scp>ll</scp> trials comparing nintedanib vs sorafenib. Liver International, 2017, 37, 1047-1055.	3.9	58
26	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	7.0	58
27	Capecitabine and streptozocin±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, 2014, 50, 902-911.	2.8	56
28	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open, 2020, 5, e000714.	4.5	51
29	Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2015, 22, L13-L18.	3.1	50
30	Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer. Clinical Cancer Research, 2021, 27, 5961-5978.	7.0	47
31	Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World Journal of Gastroenterology, 2019, 25, 5991-6005.	3.3	43
32	Goblet cell appendiceal tumors – Management dilemmas and long-term outcomes. Surgical Oncology, 2015, 24, 47-53.	1.6	41
33	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040 Journal of Clinical Oncology, 2018, 36, 475-475.	1.6	39
34	Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs. PLoS ONE, 2015, 10, e0125553.	2.5	37
35	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
36	Expression of somatostatin receptors 2 and 5 in circulating tumour cells from patients with neuroendocrine tumours. British Journal of Cancer, 2016, 115, 1540-1547.	6.4	33

TIM MEYER

#	Article	IF	CITATIONS
37	Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study Journal of Clinical Oncology, 2016, 34, 4078-4078.	1.6	30
38	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver International, 2020, 40, 215-228.	3.9	27
39	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. British Journal of Cancer, 2019, 120, 294-300.	6.4	25
40	Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Review of Anticancer Therapy, 2013, 13, 359-373.	2.4	24
41	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 563-570.	3.1	24
42	Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours. British Journal of Cancer, 2016, 115, 1321-1327.	6.4	24
43	Imaging in targeted delivery of therapy to cancer. Targeted Oncology, 2009, 4, 201-217.	3.6	23
44	Streptozocin-based chemotherapy is not history in neuroendocrine tumours. Targeted Oncology, 2012, 7, 161-168.	3.6	22
45	Sarcoidosis and testicular cancer: A case series and literature review. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 350-354.	1.6	20
46	Liquid Biopsies for Neuroendocrine Tumors: Circulating Tumor Cells, DNA, and MicroRNAs. Endocrinology and Metabolism Clinics of North America, 2018, 47, 471-483.	3.2	20
47	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer, 2022, 11, 38-47.	7.7	20
48	Treatment of advanced hepatocellular carcinoma: beyond sorafenib. The Lancet Gastroenterology and Hepatology, 2018, 3, 218-220.	8.1	19
49	Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study Journal of Clinical Oncology, 2017, 35, 226-226.	1.6	19
50	Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial Journal of Clinical Oncology, 2019, 37, 4088-4088.	1.6	19
51	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. Clinical Cancer Research, 2022, 28, 3443-3451.	7.0	19
52	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). Neuroendocrinology, 2019, 108, 317-327.	2.5	16
53	Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. British Journal of Cancer, 2021, 125, 1350-1355.	6.4	15
54	Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Annals of Translational Medicine, 2015, 3, 118.	1.7	14

TIM MEYER

#	Article	IF	CITATIONS
55	Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers, 2022, 14, 504.	3.7	14
56	Roles of miR-196a on gene regulation of neuroendocrine tumor cells. Molecular and Cellular Endocrinology, 2015, 412, 131-139.	3.2	12
57	Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 872-882.	3.6	12
58	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 2020, 10, e034527.	1.9	11
59	Role of everolimus in pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1653-1665.	2.4	10
60	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. Frontiers in Oncology, 2020, 10, 971.	2.8	10
61	Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. British Journal of Cancer, 2022, 126, 569-575.	6.4	10
62	Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer, 2022, 22, 377.	2.6	10
63	Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours. Journal of Neuroendocrinology, 2022, 34, e13096.	2.6	9
64	Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 631-644.	3.1	8
65	Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426) Journal of Clinical Oncology, 2014, 32, TPS4150-TPS4150.	1.6	7
66	Stereotactic body radiotherapy for hepatocellular carcinoma – still searching for a role. Journal of Hepatology, 2020, 73, 15-16.	3.7	6
67	A Realâ€World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARCETâ€HCC. Hepatology Communications, 2021, 5, 538-547.	4.3	6
68	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2018, 36, 4088-4088.	1.6	6
69	mRECIST for systemic therapies: More evidence is required before recommendations can be made. Journal of Hepatology, 2017, 67, 195.	3.7	5
70	Sorafenib and hepatic arterial infusion chemotherapy: another failed combination. The Lancet Gastroenterology and Hepatology, 2018, 3, 376-377.	8.1	4
71	VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. JMIR Research Protocols, 2019, 8, e13696.	1.0	4
72	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. Clinical Cancer Research, 2022, 28, 2657-2668.	7.0	4

Tim Meyer

#	Article	IF	CITATIONS
73	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. Neuroendocrinology, 2020, 111, 863-875.	2.5	3
74	Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2019, 37, 305-305.	1.6	2
75	Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2022, 40, 434-434.	1.6	2
76	Status of hepatocellular cancer in Europe. Chinese Clinical Oncology, 2013, 2, 44.	1.2	2
77	Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 1060-1061.	3.7	1
78	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2020, 38, 4601-4601.	1.6	1
79	A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC) Journal of Clinical Oncology, 2022, 40, TPS485-TPS485.	1.6	1
80	Oncotherapies for HCC. , 2019, , 153-165.		0
81	Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. Journal of Vascular and Interventional Radiology, 2022, , .	0.5	0